TG Therapeutics (TGTX) announced that it has completed its previously authorized $100M share repurchase program, which was initially announced in August 2024. Under that program, the Company repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. In addition, the Company’s Board of Directors has authorized a new share repurchase program to acquire up to an additional $100 million of TG Therapeutics’ common stock. Repurchases under this new program may be made from time to time through open market purchases, privately negotiated transactions, or other means, in accordance with applicable securities laws and subject to market conditions and other factors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges
- TG Therapeutics files automatic mixed securities shelf
- TG Therapeutics’ Earnings Call Highlights BRIUMVI Success
- TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales
- Tesla grants Musk big payout, Wayfair reports Q2 beat: Morning Buzz